Vectura Group announces positive findings from its VR647 Phase II pharmacokinetic studies
Vectura successfully concludes two paediatric studies to support the potential use of VR647, its wholly-owned drug/device combination asset.
The trials investigated children across different age settings, and results from both studies provide high confidence in the programme. August 21, 2018